The Gata2-L359V mutation has been initially identified by our group as an aberrant transcription factor in cooperation with BCR/ABL fusion gene in CML patients with myelomonoblastic transformation25. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.